The 39th annual convention of the Huntington’s Disease Society of America (HDSA) is launching this evening for “three days of education, support and camaraderie!” The convention, which runs from May 30 to June 1, offers many opportunities for attendees to learn about Huntington’s disease and to connect…
Small molecules developed by Design Therapeutics were able to reduce the activity of the disease-causing mutant gene in preclinical models of Huntington’s disease, according to an announcement from the company. “We are highlighting an exciting new program for Huntington’s Disease, an indication of tremendous unmet medical need,”…
A first clinical trial of SKY-0515, an experimental treatment for Huntington’s disease, is starting to give multiple ascending doses to healthy adults randomized to the therapy rather than a placebo, Skyhawk Therapeutics, its developer, announced. Initiation of this part of the Phase 1 trial (ACTRN12623001161617), taking place in…
The Huntington’s Disease Society of America (HDSA) has awarded grants totaling more than $2.1 million to support its Centers of Excellence, which include multidisciplinary care teams with a track record of providing exemplary care for people with Huntington’s disease and their families. A total of 57 institutions…
Eating a high-fiber diet led to improvements in memory and reductions in depression-like behavior in a mouse model of Huntington’s disease, a new study reports. “What we found is very exciting. For the first time we’ve shown that high-fiber intake not only enhanced gastrointestinal function, it also improved cognition…
A newly launched company known as HD Immune, based in Vienna, is working to develop an antibody treatment for Huntington’s disease. The potential therapy showed promise in a mouse model, according to the study, “Reducing huntingtin by immunotherapy delays disease progression in a mouse…
The Huntington’s Disease Society of America (HDSA) has awarded $898,194 in funding to support six research projects aiming to better understand and find more effective treatments for Huntington’s disease (HD). Grants were awarded through the HD Human Biology Project, HDSA’s largest research initiative supporting work focused…
Harness Therapeutics has secured an additional £4 million (about $5 million) in funding, which the U.K. biotech company plans to use to advance development of an experimental treatment for Huntington’s disease. “This further investment puts us in a strong position to address multiple neurodegenerative disease pathways, with an…
Nearly a year of treatment with Neurocrine Biosciences’ Ingrezza (valbenazine) leads to sustained reductions in uncontrolled movements known as chorea in adults with Huntington’s disease, according to interim data from a Phase 3 trial called KINECT-HD2. “The 50-week data from the ongoing KINECT-HD2 study provide insight on the…
A four-week titration kit for starting on Austedo (deutetrabenazine) — an approved therapy for chorea, or involuntary muscle contractions, due to Huntington’s disease — has so far been well-received by patients in a Phase 4 clinical trial. Titration, in medicine, means starting a drug at a low dose…
Get regular updates to your inbox.
